Ingevity (NYSE:NGVT – Get Free Report) is anticipated to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Ingevity to post earnings of $0.29 per share and revenue of $297.40 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Ingevity Stock Performance
Ingevity stock opened at $45.01 on Monday. The firm’s 50 day simple moving average is $43.34 and its 200-day simple moving average is $40.88. The company has a market cap of $1.64 billion, a P/E ratio of -2.90 and a beta of 1.64. The company has a debt-to-equity ratio of 6.52, a current ratio of 1.76 and a quick ratio of 1.04. Ingevity has a fifty-two week low of $30.90 and a fifty-two week high of $56.29.
Analyst Upgrades and Downgrades
Separately, BMO Capital Markets lifted their target price on shares of Ingevity from $40.00 to $47.00 and gave the stock a “market perform” rating in a research report on Thursday, October 31st. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.17.
About Ingevity
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Read More
- Five stocks we like better than Ingevity
- EV Stocks and How to Profit from Them
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- 3 Small Caps With Big Return Potential
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- NYSE Stocks Give Investors a Variety of Quality Options
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.